CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery.
Trends Cancer. 2016 Jun;2(6):313-324
Authors: Luo J
Advances in translational research are often driven by new technologies. The advent of microarrays, next-generation sequencing, proteomics and RNA interference (RNAi) have led to breakthroughs in our understanding of the mechanisms of cancer and the discovery of new cancer drug targets. The discovery of the bacterial clustered regularly interspaced palindromic repeat (CRISPR) system and its subsequent adaptation as a tool for mammalian genome engineering has opened up new avenues for functional genomics studies. This review will focus on the utility of CRISPR in the context of cancer drug target discovery.
PMID: 28603775 [PubMed – in process]